Cash tender offer meaning

See full statement. Dordaviprone tackles a major unmet need for people with rare, high‑grade brain tumours. Deal to introduce a near‑term commercial prospect to Jazz’s pipeline. The agreement reflects cash consideration of roughly $935m, equating to $8.55 per share. DUBLIN and DURHAM, NC, 4 March March 2025 (GLOBE NEWSWIRE) Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (‘Jazz’ or the ‘Company’) and Chimerix (Nasdaq: CMRX) (‘Chimerix’) today reported they have signed a definitive agreement under which Jazz will acquire Chimerix for $8.55 per share in cash, for total consideration of approximately $935m. The deal has received approval from both businesses and is targeted to complete in the second quarter of 2025. Chimerix’s lead clinical asset, dordaviprone, is a novel, first‑in‑class small molecule in development for H3 K27M‑mutant diffuse glioma, a rare, high‑grade brain tumour that most often affects children and young adults. There are currently no US Food and Drug Administration (FDA)‑approved treatments specifically for patients with H3 K27M‑mutant diffuse glioma; radiotherapy remains the most common approach. A New Drug Application (NDA)...

Provided the conditions in the Companies Act 2006 (CA 2006) are satisfied, a limited company may repurchase shares it has in issue. This is referred to as a share buyback or a ‘purchase of own shares’. Beyond the CA 2006 provisions, additional requirements apply to listed and AIM companies. In particular, a listed company must consider the UK Listing Rules (UKLR) and the Disclosure Guidance and Transparency Rules (DTR), and an AIM company must comply with the AIM Rules. Such companies might also need to take account of institutional investor guidelines. The CA 2006 restrictions on buybacks do not extend to unlimited companies, which are not discussed further in this subtopic. What are share buybacks? Why do a share buyback? Companies undertake share buybacks for a range of motives. One common rationale is to return excess cash to shareholders where there is no defined use for it and it cannot be invested to generate a return above the cost of capital. For further reasons why a company might...

This Resource Note summarises the key provisions of Appendix 5 to The City Code on Takeovers and Mergers (the Code), addressing tender offers. It signposts pertinent materials, commentary and guidance from the Panel on Takeovers and Mergers (the Panel), together with Lexis+® UK analysis and resources, to offer practical assistance on interpreting and applying Appendix 5. Materials referenced in this Resource Note comprise: Practice Statements issued by the Panel Executive—the body responsible for the day‑to‑day oversight and regulation of takeovers (Executive)—providing informal insight into the Executive’s usual approach to construing and operating the Code Panel Statements (P/S) released by the Panel, and Panel Instruments Public Consultation Papers (PCP) and Response Statements (RS) issued by the Code Committee Annual Reports of the Panel discussing broad matters (Annual Reports) relevant Lexis+® UK resources Together, these sources provide context, examples and expectations to inform practice and support consistent, compliant execution of tender offer processes. Appendix 5—Setting the scene Code and Lexis+®...

This Practice Note sets out essential tips for advising a client weighing a liability management transaction. Amid recurring market swings, issuers across numerous sectors periodically assess options such as debt buy-backs, tender or exchange offers, and consent solicitations. Such transactions enable an issuer to refinance or reorganise outstanding obligations and, in certain circumstances, to satisfy accounting, regulatory, or tax aims. The potential advantages can be considerable, ranging from signalling confidence to the market to avoiding more drastic measures. Extending debt maturities Recognising an accounting gain Deleveraging Securing possible regulatory capital benefits Enhancing financing flexibility Potentially forestalling a deeper restructuring or bankruptcy Demonstrating a positive outlook in an uncertain market environment Selecting the most suitable liability management route is critical, requiring issuer and counsel to weigh multiple considerations, as outlined below. Deciding between repurchases, tender or exchange offers, and consent solicitations will turn on the issuer’s objectives, constraints, and overall financial condition. Consider whether the transaction is an...